Exp Clin Endocrinol Diabetes 2010; 118(9): 577-585
DOI: 10.1055/s-0029-1237699
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

False Positive test Results for Pheochromocytoma from 2000 to 2008

R. Yu1 , M. Wei2
  • 1Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, California
  • 2Cedars-Sinai Medical Care Foundation, Beverly Hills, California
Further Information

Publication History

received 24.02.2009 first decision 02.07.2009

accepted 30.07.2009

Publication Date:
08 December 2009 (online)

Abstract

Testing for pheochromocytoma becomes more frequent in clinical practice. False positive test results may cause patient anxiety and unnecessary imaging studies. The data on false positive results for pheochromocytoma in routine clinical practice are lacking. To examine the prevalence of false positive results and to reveal the clinical features and laboratory tests of patients with markedly elevated but false positive test results, a database of tests for pheochromocytoma at a large general hospital between 2000 and 2008 was reviewed. Of 1 896 patients tested, 417 (22.0%) had at least one abnormal test result and 66 (3.5%) had markedly elevated results. 24 patients with markedly elevated but false positive results received 65 imaging studies and 1 adrenalectomy. The causes of the misleading results included physiological variations (33%), laboratory errors (29%), and drug interference with measurement (21%). The false positive rate of a markedly elevated result was lowest for vanillylmandelic acid (9%) and highest for urine metanephrines (50%) (p=0.03). Nearly half of all test results were normal and 79% of patients had at least one normal result. Therefore false positive test results for pheochromocytoma are rather common. Markedly elevated but false positive test results can potentially be avoided by judicious selection of patients and tests. Pretest risk, physiological variations of catecholamine levels, laboratory errors, and drug interference should be considered in interpreting abnormal test results.

References

  • 1 Brook RD. How to achieve control in managing hypertension?.  ACC Curr J Rev. 2002;  11 35-40
  • 2 Eisenhofer G, Huynh TT, Hiroi M. et al . Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma.  Rev Endocr Metab Disord. 2001;  2 297-311
  • 3 Eisenhofer G, Goldstein DS, Walther MM. et al . Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.  J Clin Endocrinol Metab. 2003;  88 2656-2666
  • 4 Elmasry A, Lindberg E, Hedner J. et al . Obstructive sleep apnoea and urine catecholamines in hypertensive males: A population-based study.  Eur Respir J. 2002;  19 511-517
  • 5 Grossman A, Pacak K, Sawka A. et al . Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?.  Ann NY Acad Sci. 2006;  1073 332-347
  • 6 Hoy LJ, Emery M, Wedzicha JA. et al . Obstructive sleep apnea presenting as pseudopheochromocytoma: a case report.  J Clin Endocrinol Metab. 2004;  89 2033-2038
  • 7 Kudva YC, Sawka AM, Young Jr WF. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience.  J Clin Endocrinol Metab.. 2003;  88 4533-4539
  • 8 Lenders JW, Keiser HR, Goldstein DS. et al . Plasma metanephrines in the diagnosis of pheochromocytoma.  Ann Intern Med. 1995;  123 101-109
  • 9 Lenders JW, Pacak K, Walther MM. et al . Biochemical diagnosis of pheochromocytoma: which test is best?.  JAMA. 2002;  287 1427-1434
  • 10 Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges.  Ann NY Acad Sci. 2006;  1073 1-20
  • 11 Nicholls KM, Shapiro MD, Van Putten VJ. et al . Elevated plasma norepinephrine concentrations in decompensated cirrhosis Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion.  Circ Res. 1985;  56 457-461
  • 12 Onusko E. Diagnosing secondary hypertension.  Am Fam Physician. 2003;  67 67-74
  • 13 Pacak K, Eisenhofer G, Ahlman H. et al . International Symposium on Pheochromocytoma. Pheochromocytoma: Recommendations for clinical practice from the First International Symposium. October 2005.  Nat Clin Pract Endocrinol Metab. 2007;  3 92-102
  • 14 Perry CG, Sawka AM, Singh R. et al . The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma.  Clin Endocrinol. 2007;  6 703-708
  • 15 Sawka AM, Jaeschke R, Singh RJ. et al . A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.  J Clin Endocrinol Metab. 2003;  88 553-558
  • 16 Sawka AM, Thabane L, Gafni A. et al . Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?.  BMC Endocr Disord. 2005;  5 1
  • 17 Young Jr WF. The incidentally discovered adrenal mass.  N Engl J Med. 2007;  356 601-610
  • 18 Yu R, Nissen NN, Chopra P. et al . Diagnosis and Treatment of Pheochromocytoma in an Academic Hospital from 1997 to 2007.  Am J Med. 2009;  122 85-95
  • 19 Zaloga GP, Chernow B, Fletcher JR. et al . Increased circulating plasma norepinephrine concentrations in noncardiac causes of pulmonary hypertension.  Crit Care Med. 1984;  12 85-89

Correspondence

R. YuMD,PhD 

Division of Endocrinology and Carcinoid and Neuroendocrine Tumor Center

Cedars-Sinai Medical Center

B-131

8700 Beverly Blvd

Los Angeles, CA 90048

Phone: 310-423-4774

Fax: 310-423-0440

Email: run.yu@cshs.org

    >